Preparation of a crystalline antibiotic substance

A technology of fusidic acid and crystallization, which is applied in the field of preparation of crystalline antibiotic fusidic acid and can solve problems such as affecting the quality of medicines

Active Publication Date: 2009-01-21
LEO PHARMA AS
View PDF7 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the presence of various solid forms such as polymorphism or pseudopolymorphism may affect the quality of the drug product

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation of a crystalline antibiotic substance
  • Preparation of a crystalline antibiotic substance
  • Preparation of a crystalline antibiotic substance

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0076] In a more particular aspect, the present invention relates to a mixture of crystalline forms of fusidic acid comprising crystalline fusidic acid of the invention as described above, wherein the mixture of crystalline forms of fusidic acid consists essentially of crystalline fusidic acid half Hydrate composition.

[0077] In another more particular aspect, the present invention relates to a mixture of crystalline forms of fusidic acid comprising crystalline fusidic acid according to the invention as described above, wherein the mixture of crystalline forms of fusidic acid comprising is characterized in that it exhibits Crystalline fusidic acid characterized by one or both of t) or u):

[0078] t) Infrared (FT-IR) spectrum (KBr) with one or more -1 ); or

[0079] u) X-ray powder diffraction pattern (XRD) having one or more 2θ values ​​(±0.1) occurring at about 2.1, 6.8, 9.4, 10.4, 11.8, 12.8, 13.7, 14.2, 15.8, 17.3, 18.5, or 22.9, respectively A characteristic intensit...

Embodiment 1

[0406] Fusidic acid hemihydrate

[0407] 17.68 kg of fusidic acid starting material obtained by fermentation was dissolved in a mixture of 69.3 L of ethanol (96%) and 2.52 L of acetone, thereby obtaining 85.5 L of the first solution. Add the first solution and 93.4 L horizontally to a vessel at ambient temperature over 17-19 minutes while mixing. Crystallization was observed immediately after mixing the solution with anti-solvent water. The mixture was mixed further and crystalline fusidic acid hemihydrate was filtered off, washed with a mixture of water and ethanol (3:1, v:v) and water. A micronized sample of this crystal (jet mill) had an endothermic peak at 186°C in DSC (20°C / min), with an onset temperature of 183°C. The crystals are vacuum dried at 50° C. for about 15-18 hours to obtain a crystalline hemihydrate characterized by exhibiting one or more of the following characteristics l)-s), respectively yes:

[0408] l) Fourier transform (FT-NIR) Raman spectrum has one...

Embodiment 2

[0417] Fusidic acid hemihydrate

[0418] 1.64 g of fusidic acid, 313 ml of ethanol, 380 ml of water and 162 mg of acetone were mixed and the saturated solution was filtered through a filter. 178 g of fusidic acid was dissolved in 693 ml of ethanol and 25 ml of acetone and the solution was filtered with a filter. The first solution was poured into a 5 liter flask and stirred in a water bath at 180 rpm at a temperature of 30°C. This solution was seeded with 0.45 g of fusidic acid hemihydrate having the properties described in Example 1. The second solution and water (934ml) were added to the flask in parallel at a rate of 7-8ml / min for a total addition time of 90 minutes. After complete addition, the crystal suspension was stirred for a further 30 minutes. The crystals were filtered off, and the crystals were dried under vacuum at 30°C for 18 hours to obtain crystalline fusidic acid hemihydrate as described in Example 1, which exhibited one or more of the following characteri...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to processes for the crystallisation and for the preparation and isolation of a novel crystalline form of fusidic acid, to the use of said processes in the manufacture of pharmaceutical formulation or medicament, and to the use of said crystalline fusidic acid form for the treatment of bacterial infections.

Description

technical field [0001] The present invention relates to a new crystal form of fusidic acid, its preparation, a pharmaceutical composition containing it and the use of the fusidic acid crystal form as a medicine for treating infectious diseases. Background technique [0002] Fusidic acid [CAS6990-06-3] [Nature, Vol. 193, No. 4819, Page 987, 1962] can be isolated from the fermentation broth of Fusidium coccineum and is a fusidane (fusidane) is the most antibiotic active compound and is the only fusidane clinically used for the treatment of infectious diseases. Fusidic acid ( ) is used clinically in the treatment of severe staphylococcal infections, especially bone and joint infections, both in the acute and intractable forms of the disease (The Use of Antibiotics, 5th edition, A. Kucers and N McK. Bennett (ed.), Butterworth 1997, pp. 580-587, and references cited therein). [0003] [0004] fusidic acid [0005] Although fusidic acid is most commonly used against staph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07J13/00A61K31/575A61P31/00
CPCC07J13/007A61P31/00A61P31/04C07J13/00A61K31/575
Inventor J·詹森N·R·安德森
Owner LEO PHARMA AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap